Banque Transatlantique SA Reduces Stake in Eli Lilly and Company

Institutional investor cuts holdings in pharmaceutical giant by 8.2% in Q3

Mar. 14, 2026 at 7:20am

Got story updates? Submit your updates here. ›

Banque Transatlantique SA, a French investment firm, reduced its stake in Eli Lilly and Company (NYSE:LLY) by 8.2% in the third quarter of 2026, according to a filing with the Securities and Exchange Commission. The firm now owns 135,589 shares of the pharmaceutical company's stock, valued at $104,176,000.

Why it matters

Eli Lilly is one of the world's leading pharmaceutical companies, known for developing innovative drugs and therapies. Institutional investors closely monitor their holdings in Lilly, as changes in ownership can signal shifts in market sentiment or strategic priorities.

The details

Banque Transatlantique SA sold 12,126 shares of Eli Lilly during the third quarter, reducing its total position to 135,589 shares. The firm's holdings in Lilly now account for approximately 2.5% of its investment portfolio, making it the 11th largest holding.

  • Banque Transatlantique SA filed its Q3 2026 disclosure with the SEC on March 14, 2026.

The players

Banque Transatlantique SA

A French investment firm that manages a diversified portfolio of public and private equity investments.

Eli Lilly and Company

A global pharmaceutical company headquartered in Indianapolis, Indiana, known for developing innovative drugs and therapies.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Banque Transatlantique's Eli Lilly holdings, while relatively small, could signal broader market trends or changes in the firm's investment strategy. Investors will likely continue to monitor institutional ownership of Eli Lilly as an indicator of sentiment around the company's performance and future prospects.